Publication:
MEST C Score and Treatment Response in IgA Nephropathy in a Tertiary Care Hospital: A Descriptive Cross-sectional Study

creativeworkseries.issnJNMA Print ISSN: 0028-2715; Online ISSN: 1815-672X
dc.contributor.authorThapa, Sushma
dc.contributor.authorSigdel, Mahesh Raj
dc.date.accessioned2025-08-03T08:39:34Z
dc.date.available2025-08-03T08:39:34Z
dc.date.issued2024
dc.descriptionSushma Thapa Department of Internal Medicine, Bharatpur Hospital, Bharatpur, Chitwan, Nepal Mahesh Raj Sigdel Department of Internal Medicine, Tribhuvan University Teaching Hospital, Maharajgunj, Kathmandu, Nepal
dc.description.abstractAbstract Introduction: IgA nephropathy is the leading cause of primary glomerulonephritis worldwide. The Oxford classification can predict IgA nephropathy prognosis through renal biopsy however its applicability to the Nepalese population remains unexplored. This study aimed to evaluate the MEST-C score and treatment response in patients with IgA nephropathy. Methods: This descriptive cross-sectional study was conducted at a tertiary care center from November 2021 to November 2022 after obtaining ethical approval [IRC-193(6-11)t2078/079]. Total population sampling was done. Fifty-two consenting patients aged 16 or older with confirmed IgA nephropathy were included, excluding those with liver disease or expected survival of less than six months. The study assessed the MEST-C score, demographic factors, and clinical parameters. Data analysis was done using Statistical Package of Social Sciences. Results: Among 52 patients with segmental glomerulosclerosis (S1), 11 (24.44%) achieved complete remission, 30 (66.67%) partial remission, and 5 (11.11%) progressed to end-stage renal disease. In those with tubular atrophy/interstitial fibrosis (T1), 1 (5.88%) achieved complete remission, 13 (76.47%) partial remission, and 4 (23.53%) progressed to end-stage renal disease. For glomerular crescents (C1), 9 (47.37%) achieved complete remission, 9 (47.37%) partial remission, and 1 (5.26%) progressed to end-stage renal disease. IFTA% of 0-25% had complete remission in 15 (46.88%). Among the two patients with IFTA% ≥50%, one (50%) developed end-stage renal disease and the other achieved partial remission. Conclusions: The S1 and T1/2 components of the MEST-C score had higher rates of partial remission and progression to end-stage renal disease, while other indices showed mixed results. The risk of failing to achieve complete increased with an IFTA of more than 25%.
dc.identifierhttps://doi.org/10.31729/jnma.8707
dc.identifier.urihttps://hdl.handle.net/20.500.14572/1182
dc.language.isoen_US
dc.publisherNepal Medical Association
dc.titleMEST C Score and Treatment Response in IgA Nephropathy in a Tertiary Care Hospital: A Descriptive Cross-sectional Study
dc.typeArticle
dspace.entity.typePublication
local.article.typeOriginal Article
oaire.citation.endPage541
oaire.citation.startPage536
relation.isJournalIssueOfPublication21a0eb7b-fe78-4c7a-90dd-9d8640f3820c
relation.isJournalIssueOfPublication.latestForDiscovery21a0eb7b-fe78-4c7a-90dd-9d8640f3820c
relation.isJournalOfPublicatione6e146a0-0ece-4aba-aa0a-6ccfbd10a12a

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
536-541.pdf
Size:
295.81 KB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.86 KB
Format:
Item-specific license agreed to upon submission
Description:

Collections